# Biotech Daily Digest ‚Äî 2026-02-14

**9 items from 2 sources**

## Summary by Source

- Endpoints News: 7 items
- Fierce Biotech: 2 items


## Endpoints News

- **[Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more](https://endpoints.news/moderna-vs-fda-paul-hudson-out-at-sanofi-why-clinical-trials-are-so-costly-and-more/)**  
  _Sat, 14 Feb 2026 11:00:17 +0000_  
  Welcome back to Endpoints Weekly! A programming note: We won‚Äôt be sending our usual newsletters on Monday, Feb. 16. Our team will be off for Presidents‚Äô Day. Our reporters closely followed several big updates this ...

- **[Gilead gets cancer drug from China-based Genhouse for $80M upfront](https://endpoints.news/gilead-gets-cancer-drug-from-china-based-genhouse-for-80m-upfront/)**  
  _Fri, 13 Feb 2026 18:53:40 +0000_  
  Gilead is buying the global rights to an oral cancer drug from Genhouse Bio, a China-based biotech that filed for an IPO on the Hong Kong Stock Exchange last month.  ...

- **[Lilly appeals retatrutide classification ruling in case that could impact compounders](https://endpoints.news/lilly-appeals-retatrutide-classification-ruling-in-case-that-could-impact-compounders/)**  
  _Fri, 13 Feb 2026 17:31:04 +0000_  
  Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it.

 On Thursday, Lilly filed a notice ...

- **[Epigenetic editing startup Moonwalk shifts focus to siRNA for obesity](https://endpoints.news/epigenetic-editing-startup-moonwalk-shifts-focus-to-sirna-for-obesity/)**  
  _Fri, 13 Feb 2026 16:14:41 +0000_  
  Two years ago, CRISPR gene editing pioneer Feng Zhang and former Illumina chief technology officer Alex Aravanis launched a startup to develop medicines that would change how genes are turned on and ...

- **[Lundbeck's migraine prevention drug succeeds in Phase 2, advancing new therapy class](https://endpoints.news/lundbeck-migraine-prevention-drug-succeeds-in-phase-2-advancing-new-therapy-class/)**  
  _Fri, 13 Feb 2026 15:55:35 +0000_  
  Lundbeck said its next-generation migraine prevention drug cleared the bar in a Phase 2b study, setting the company up for late-stage trials that could start this year.

 The Danish drugmaker said the IV-delivered medicine, bocunebart ...

- **[Moderna's flu shot dilemma muddies 2028 break-even guidance](https://endpoints.news/modernas-flu-shot-dilemma-muddies-2028-break-even-guidance/)**  
  _Fri, 13 Feb 2026 15:55:13 +0000_  
  Moderna‚Äôs finance chief said it's ‚Äútoo early to tell‚Äù whether the company‚Äôs goal of reaching break-even cash flow will be pushed back ‚Äî once again ‚Äî after the FDA declined to review its flu ...

- **[Immunic's private placement; Vertex's cystic fibrosis data in young kids](https://endpoints.news/immunics-private-placement-vertexs-cystic-fibrosis-data-in-young-kids/)**  
  _Fri, 13 Feb 2026 14:45:37 +0000_  
  Plus, news about Novartis' Vanrafia and Evommune:

 üí∞ Immunic gets up to $400M, will search for new CEO: The company said it will receive $200 million upfront and another $200 million ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/pharma/fdas-moderna-decision-drugmakers-face-increasingly-uncertain-regulatory-environment" hreflang="en">With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment</a>](https://www.fiercebiotech.com/pharma/fdas-moderna-decision-drugmakers-face-increasingly-uncertain-regulatory-environment)**  
  _Feb 13, 2026 10:30am_  
  The regulatory environment in the United States encountered by Moderna during the development of its COVID-19 vaccine bears little resemblance to what the company experienced earlier this week when the FDA refused to review its application for approval of its flu shot mRNA-1010. Mani Foroohar, M.D., of Leerink Partner‚Ä¶

- **[<a href="https://www.fiercebiotech.com/biotech/moderna-rd-spend-drops-31-2025" hreflang="en">Moderna R&amp;D spend shrunk 31% in 2025 amid major pipeline reorg</a>](https://www.fiercebiotech.com/biotech/moderna-rd-spend-drops-31-2025)**  
  _Feb 13, 2026 8:54am_  
  Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials.
